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The CD40–CD40 ligand (CD40L) signaling axis plays an important role in immunological
pathways. Consequently, this dyad is involved in chronic inflammatory diseases, including
atherosclerosis. Inhibition of CD40L in apolipoprotein E (Apoe)–deficient (Apoe/) mice
not only reduced atherosclerosis but also conferred a clinically favorable plaque phenotype
that was low in inflammation and high in fibrosis. Blockade of CD40L may not be therapeutically feasible, as long-term inhibition will compromise systemic immune responses.
Conceivably, more targeted intervention strategies in CD40 signaling will have less deleterious side effects. We report that deficiency in hematopoietic CD40 reduces atherosclerosis
and induces features of plaque stability. To elucidate the role of CD40–tumor necrosis
factor receptor-associated factor (TRAF) signaling in atherosclerosis, we examined disease
progression in mice deficient in CD40 and its associated signaling intermediates. Absence of
CD40-TRAF6 but not CD40-TRAF2/3/5 signaling abolishes atherosclerosis and confers
plaque fibrosis in Apoe/ mice. Mice with defective CD40-TRAF6 signaling display a
reduced blood count of Ly6Chigh monocytes, an impaired recruitment of Ly6C+ monocytes to
the arterial wall, and polarization of macrophages toward an antiinflammatory regulatory
M2 signature. These data unveil a role for CD40–TRAF6, but not CD40–TRAF2/3/5, interactions in atherosclerosis and establish that targeting specific components of the CD40–
CD40L pathway harbors the potential to achieve therapeutic effects in atherosclerosis.
CORRESPONDENCE
Esther Lutgens:
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Abbreviations used: Apoe, apolipoprotein E; CD40L, CD40 li
gand; Ldlr, low-density lipoprotein
receptor; mRNA, messenger
RNA; SMA, smooth muscle
actin; SMC, smooth muscle cell;
TIMP, tissue inhibitor of metal
loproteinase; TRAF, TNF
receptor-associated factor.

Atherosclerosis is a chronic inflammatory disease
of the large arteries that involves multiple immuno
logical processes (Hansson, 2005; Weber et al.,
2008). During the progression of atherosclerosis,
ongoing activation of the immune system causes
continuous recruitment of inflammatory cells
into the plaque and degradation of its extracellular
E.A. Biessen and C. Weber contributed equally to this paper.
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matrix. This creates a so-called vulnerable plaque,
which is prone to rupture and therefore likely to
cause acute complications such as myocardial in
farction or stroke (Virmani et al., 2000).
© 2010 Lutgens et al. This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the
publication date (see http://www.jem.org/misc/terms.shtml). After six months it is
available under a Creative Commons License (Attribution–Noncommercial–Share
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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The CD40–CD40 ligand (CD40L) dyad, a costimulatory
receptor-ligand pair, plays a crucial role in enhancing immune
responses and inflammation and contributes to a plethora of
chronic inflammatory diseases, for example, colitis, arthritis, al
lergic encephalitis, and multiple sclerosis (Durie et al., 1993;
Gerritse et al., 1996; Lutgens et al., 2007; Vowinkel et al.,
2007). Disruption of the CD40L gene in apolipoprotein E
(Apoe)/ mice abrogated atherosclerosis and caused a plaque
phenotype with only few inflammatory cells and a high per
centage of extracellular matrix (Lutgens et al., 1999), which is
reminiscent of a clinically favorable stable atherosclerotic plaque
in humans (Virmani et al., 2000). This phenotype was copied
when Apoe/ mice with initial plaques or established athero
mata were treated with a blocking anti-CD40L antibody (Mach
et al., 1998; Lutgens et al., 2000; Schönbeck et al., 2000).
In principle, these findings render targeting of CD40L a
promising strategy to reduce atherosclerosis and to stabilize
atherosclerotic plaques. Unfortunately, clinical trials using an
anti-CD40L antibody have been omitted as a result of throm
boembolic complications, particularly because CD40L is pres
ent on platelets and can interact with the integrin IIb3 in
platelets (Kawai et al., 2000; André et al., 2002).
Antagonizing CD40, the receptor for CD40L, or its sig
naling intermediates would be an alternative approach for
treating human atherosclerosis. However, information on the
effects of CD40 and CD40-associated signal transduction
pathways in atherosclerosis is scarce. It has been shown that
low-density lipoprotein receptor (Ldlr)–deficient (Ldlr/) mice
lacking the CD40 gene do not develop smaller atheroscle
rotic lesions than control Ldlr/ mice (Zirlik et al., 2007b),
although a proatherogenic role for endothelial CD40–TNF
receptor-associated factor (TRAF) 1, 2, 3, 5, and 6 signaling
in atherosclerosis has been claimed (Zirlik et al., 2007a). Using
mice carrying a CD40 transgene with targeted mutations at
the CD40-TRAF6 recognition site, we found that CD40TRAF6 signaling is specifically required for arterial neointima
formation (Donners et al., 2008).
In the present study, we tried to elucidate the role of
CD40 and its associated signaling intermediates, the TRAFs,
in primary atherosclerosis in vivo in detail. We found that
CD40/Apoe/ mice had a reduction in atherosclerosis
and developed a stable atherosclerotic plaque phenotype. BM
transplantation of CD40/ BM into Ldlr/ mice revealed
that hematopoietic CD40 was responsible for the observed
phenotype. Surprisingly, when CD40–TRAF6, but not
CD40–TRAF2/3/5, interactions were defective, atheroscle
rosis was completely abrogated.
RESULTS
CD40 deficiency reduces atherosclerosis
We generated CD40/Apoe/ mice and analyzed the extent
and phenotype of atherosclerosis at 26 wk of age on a normal
chow diet. Body weight, as well as cholesterol content or plasma
sCD40L levels did not differ between the groups (Table I).
As in CD40L/Apoe/ mice, deficincy of CD40 reduced
the atherosclerotic plaque area in the aortic arch and its branch
392

Table I. Body weights, plasma cholesterol levels, and sCD40L
serum levels did not differ between the genotypes (P > 0.05)
Genotype
Apoe/
CD40/Apoe/
CD40-Twt
CD40-T2/3/5/
CD40-T6/
CD40-T2/3/5/6/

Body weight

Cholesterol

sCD40L

g
28.7 ± 0.8
29.2 ± 0.8
26.1 ± 0.8
24.9 ± 0.7
24.8 ± 0.8
28.9 ± 0.7

mg/dl
275 ± 16
299 ± 24
328 ± 26
297 ± 33
283 ± 12
330 ± 36

ng/ml
4.0 ± 0.8
5.6 ± 1.6
3.3 ± 1.0
5.0 ± 2.6
2.9 ± 0.5
5.3 ± 1.9

points, as well as in the thoraco-abdominal aorta (Fig. 1 a).
This was associated with a less inflammatory and more fi
brotic plaque quality, as reflected by the low amount of thin
fibrous cap atheromata (Virmani et al., 2000) that developed
in absence of CD40 (Fig. S1 a). The absence of CD40 reduced
the lipid core size (ApoE/, 35.4% vs. CD40/ApoE/,
23.3%; P < 0.05), the number of plaque macrophages, and
the content of CD45+ cells and CD3+ T lymphocytes (Figs. 1,
b and c). The number of Foxp3+ regulatory T cells in plaque
or adventitia was unaffected (Fig. S1, b and c). The numbers
of cleaved caspase 3+ (apoptotic) cells (Fig. S1 d), as well as the
degree of iron or fibrin deposition in the plaque (not depicted),
were unaffected.
Besides the decrease in inflammatory cell content, plaques
of CD40/Apoe/ mice had a more fibrotic appearance.
The content of –smooth muscle actin (SMA; -SMA+ cells;
Fig. 2 a) and collagen (Fig. 2 b) was significantly increased.
Bright-field polarization microscopy revealed that in the ab
sence of CD40, the color distribution of the collagen devi
ated toward the red spectrum, indicating larger collagen
fibrils (MacKenna and Omens, 1996). Concordant with these
findings, we found an increase in the amount of collagen I
and III in the plaque (Fig. 2, d and e).
Recent studies have identified the involvement of various
matrix metalloproteinases in atherosclerotic lesion formation
and their contribution to fibrous cap thinning by degrading
extracellular matrix (Hansson and Libby, 2006). Interestingly,
MMP-2 and MMP-9 expression was decreased in the plaques
of CD40/Apoe/ mice (Fig. S2, a and b). To confirm an
impairment of proteolytic activity and effects of tissue inhibi
tor of metalloproteinase (TIMP) 1, we measured gelatinase
activity and TIMP-1 messenger RNA (mRNA) levels in
macrophages stimulated with the CD40-clustering antibody
FGK45. We found that gelatinase activity was decreased
(Fig. S2 c), whereas TIMP-1 levels were increased in CD40deficient macrophages (Fig. S2 d).
Leukocyte CD40 deficiency reduces atherosclerosis
and impairs macrophage migration
To unequivocally establish the involvement of leukocyte
versus nonleukocyte CD40 in atherosclerosis, we reconsti
tuted lethally irradiated Ldlr/ mice with CD40/ or WT
BM and fed the mice with a high-fat diet for 24 wk. Body
CD40-TRAF6 signaling in atherosclerosis | Lutgens et al.

Ar ticle

Figure 1. Role of CD40 in atherosclerosis. (a–c) Apoe/ mice (n = 19) were fed a normal chow diet for 26 wk and were compared with CD40/
Apoe/ (n = 16). Sections of the aortic arch and its main branch points (brachiocephalic artery, right subclavian artery, right carotid artery, left carotid
artery, and left subclavian artery) were stained with hematoxylin and eosin (HE; representative sections in a, bottom) to analyze the extent of atherosclerosis (plaque area; a, top left: plaque area aortic arch and branch points; a, top right: en face staining thoraco-abdominal aorta; bars, 2 mm; horizontal
bars represent mean) and plaque phenotype (b and c). (b) Macrophage infiltration was expressed as the absolute number of Mac3+ cells per plaque (bars,
100 µm). (c) CD45 and CD3 content were expressed as the percentage of CD3+ or CD45+ cells of all plaque cells (arrows indicate CD45+ cells; bars, 50 µm).
Error bars represent mean ± SEM. *, P < 0.05.
JEM VOL. 207, February 15, 2010
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Figure 2. Deficiency of CD40 induces plaque fibrosis. Sections of the aortic arch and its main branch points (brachiocephalic artery, right and left
subclavian artery, and right and left carotid artery) of Apoe/ mice (n = 19) and CD40/Apoe/ (n = 16) mice fed a normal chow diet for 26 wk were
stained for -SMA to detect the content of SMCs (a, representative sections on the left; bars, 50 µm), which was quantified as the percentage of -SMA–
positive plaque area (a, right). (b and c) Consecutive sections were stained with Sirius red to assess the content of collagen in the plaque by light (b) and
polarized light (c) microscopy (representative sections on the left; bars, 50 µm). In addition, the content of collagen was expressed as the percentage of
-SMA–positive plaque area (b, right) and the color spectrum obtained using polarization microscopy was analyzed (c, right). (d and e) The content of
collagen I (d) and collagen III (e) was assessed by immunohistochemistry (representative sections on the left; bars, 100 µm) and expressed as the percentage of positively stained plaque area (right). Error bars represent mean ± SEM. *, P < 0.05.
394
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weights and plasma cholesterol levels did not differ between
the groups (body weight, 20.1 vs. 19.7 g in Ldlr/; P > 0.05;
cholesterol, 368 vs. 357 mg/dL Ldlr/). Chimeric Ldlr/
mice with CD40/ BM exhibited markedly reduced ath
erosclerosis in the aortic arch including its branch points and
in the thoraco-abdominal aorta (Fig. 3 a). Similar to CD40/
Apoe/ mice, atherosclerotic plaques of chimeric CD40/
Ldlr/ mice contained less Mac3+ macrophages (Fig. 3 b).
In culture, CD40/ macrophages showed an impaired mi
gration toward CCL2 (Fig. 3 c). Moreover, the percentage of
CD45+ cells and CD3+ T lymphocytes in the plaque was de
creased (Fig. 3 e). In accordance with this antiinflammatory
profile in the plaque, absence of CD40 strongly decreased
the expression of IB in FGK45-stimulated macrophages
(Fig. 3 d), suggesting that the phenotypic effects are mediated by
NF-B signaling. Total collagen content (Fig. 3 f) and smooth
muscle cell (SMC) content (Fig. 3 f) were increased in the
plaque in absence of CD40. These data reveal a crucial role for
leukocyte-dependent CD40 signaling in atherosclerosis.
Deficiency of CD40 polarizes macrophages toward
an M2 phenotype
Stimulation of CD40 with the clustering antibody FGK45 in
BM-derived macrophages resulted in a significant induction of
the proinflammatory cytokines IL-12, iNOS (Fig. 4 a), and
CCL-2 (not depicted) and a significant reduction of IL-10
(Fig. 4 c) in WT but not in CD40/ macrophages, indicating
that absence of CD40 polarizes macrophages toward an M2
phenotype (Martinez et al., 2009). To further differentiate the
M2 subset into wound-healing and regulatory macrophages
(Mosser and Edwards, 2008), real-time PCR analysis for re
spective markers was performed in FGK45-stimulated BMderived macrophages. We observed that CD40 deficiency
significantly reduced the inflammatory M1 markers iNOS and
IL-12 (Fig. 4 a), only slightly reduced the expression of the
wound-healing macrophage markers YM-1 and RELM-,
and did not affect the expression of arginase-I, IGF-1, or
DCIR (Fig. 4 b), suggesting that CD40 signaling is essential for
polarization of macrophages toward the M1 subtype but not
toward wound-healing macrophages. Moreover, absence of
CD40 did not result in an increase in collagen 1A1 produc
tion in these macrophages (Fig. 4 b). In contrast, deficiency of
CD40 strongly induced the regulatory macrophage marker
IL-10, whereas SPKH1 expression was not affected (Fig. 4 c),
indicating that CD40 deletion shifts the macrophage pheno
type to an antiinflammatory regulatory signature.
CD40 deficiency affects T cell and DC phenotype
To elaborate on the immune phenotyping, we performed
flow cytometry analysis of blood, spleen, and lymph node cells
(Fig. S3). Consistent with the atherosclerotic phenotype, anal
ysis of the different T lymphocyte and DC subsets revealed
an antiinflammatory profile in CD40/Apoe/ versus
Apoe/ mice. Whereas effector memory (CD44highCD62Llow)
CD4+ and CD8+ T lymphocytes were decreased, naive (CD
44lowCD62Lhigh) CD4+ and CD8+ T lymphocytes were increased
JEM VOL. 207, February 15, 2010

(Fig. S3 a). Moreover, CD11c+CD8CD4+ DCs, a popula
tion associated with antiinflammatory responses, was more
prominent, whereas CD11c+CD4CD8 and plasmacytoid
DCs, populations associated with proinflammatory responses,
were reduced (Fig. S3 b) (Shortman and Liu, 2002).
CD40-TRAF signaling in atherosclerosis
We next examined which of the CD40-associated signal
transduction pathways was responsible for the phenotype
observed in CD40/Apoe/ mice. CD40 has no intrinsic
signaling ability but requires adaptor molecules, TRAFs, to
confer signaling. The cytoplasmic tail of CD40 contains three
binding domains: a proximal domain that binds TRAF6 and
two distal domains that bind TRAF1, TRAF2, TRAF3, and,
indirectly, TRAF5 (Zapata, 2003; Lu et al., 2007; Lutgens
et al., 2007). The separate TRAF binding sites are coupled to
divergent signaling pathways involving different CD40
downstream modulators and effectors (Lutgens et al., 2007;
Engel et al., 2009; Lievens et al., 2009), depending on the
target cell types involved. To unravel the contribution of
CD40-TRAF2/3/5 versus CD40-TRAF6 signaling in MH
CII+ cells to atherosclerosis, we used CD40/ mice express
ing a chimeric CD40 transgene with mutations at the TRAF6
and/or TRAF2/3/5 binding site under control of the MH
CII promotor (CD40-T2/3/5/, CD40-T6/, and CD40T2/3/5/6/ mice, respectively) or CD40/ mice carrying
the transgene without mutations (CD40-Twt mice; Ahonen
et al., 2002; Donners et al., 2008) and backcrossed them with
Apoe/ mice. At 26 wk of age on a normal chow, atheroscle
rosis was analyzed in the aortic arch, including its main branch
points, and the thoraco-abdominal aorta, including the iliac
artery bifurcation (unpublished data). Body weight, plasma
cholesterol level, and serum sCD40L level did not differ be
tween the genotypes (Table I).
CD40-TRAF2/3/5 signaling does not affect atherosclerosis
The atherosclerotic plaque area, the plaque phenotype (Virmani
et al., 2000), the plaque quality, as evident by the content of
the lipid core, Mac-3+ cells, CD45+ cells, CD3+ T cells, collagen
(I and III), SMCs, cleaved caspase 3, and macrophage polarization
did not differ between CD40-T2/3/5/ and CD40-Twt mice,
indicating that deficiency in CD40-TRAF2/3/5 signaling
does not affect atherosclerosis (Figs. 5 and 6). In fact, CD40T2/3/5/ mice displayed even higher numbers of CD4+ cells
(Fig. S4 a) and CD8+CD44highCD62Llow effector memory T
lymphocytes in blood, spleen, and/or lymph nodes than CD40Twt mice and elevated CD8+ resident DCs (Fig. S3, c and d), a
subtype which is characterized by increased IL-12 production
(Shortman and Liu, 2002). This apparently proinflamma
tory profile was counterbalanced by elevated numbers of
CD4+CD25+FoxP3+ regulatory T lymphocytes in blood,
spleen, and lymph nodes of CD40-T2/3/5/ mice (Fig. S4 b).
Regulatory T cell function had not changed (Fig. S4 c), and
because of the balanced effector T cell and regulatory T cell ra
tio systemic levels of IFN-, IL-6, TNF-, IL-12, or IL-10
were unaltered (not depicted). Notably, in CD40-T2/3/5/
395

Figure 3. Role of hematopoietic cell–derived CD40 in diet-induced atherosclerosis. (a–f) WT→Ldlr/ chimeras (n = 19) were fed a normal chow
diet for 26 wk and were compared with CD40/→Ldlr/ BM chimeras (n = 19). Sections of the aortic arch and its main branch points (brachiocephalic
artery, right and left subclavian artery, and right and left carotid artery) were stained with hematoxylin and eosin and the thoraco-abdominal aorta was
stained with Sudan IV (representative examples in a, right) to analyze the extent of atherosclerosis (a, left: plaque area in the arch; a, middle: plaque area
in the thoraco-abdominal aorta; horizontal bars represent mean) and phenotype (b–f). (b) Macrophage infiltration was expressed as the absolute number
of Mac3+ cells per plaque (bars, 100 µm). (c) Migration of BM-derived macrophages toward CCL2 for 4 h was analyzed in a Transwell migration assay (n =
6 per group, three independent experiments). (d) Levels of IB in FGK45-stimulated macrophages were determined by real-time PCR (n = 6). (e) CD45
and CD3 content were expressed as the percentage of CD3+ or CD45+ cells of all plaque cells (arrows indicate CD45+ cells; bars, 50 µm). (f) The content of
collagen (representative sections on the right; bars, 100 µm) and -SMA was expressed as the percentage of positively stained plaque area. Error bars
represent mean ± SEM. *, P < 0.05.
396
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mice the content of CD4+CD25+FoxP3+ regulatory T lym
phocytes was also increased in the adventitia underlying the
plaques but not in the plaque itself (Fig. S4 d).
Inhibition of CD40-TRAF6 signaling abolishes atherosclerosis
In a remarkable contrast, deficiency of CD40-TRAF6 signal
ing almost completely abolished the development of athero
sclerosis, as only few intimal xanthomas or fatty-streak lesions
(classified according to Virmani et al. [2000]) were detectable
in the aortic arch and its branch points (Fig. 5 a), and no plaques
were present in the thoraco-abdominal aorta of CD40-T6/
mice (Fig. 5 a). This reduction of atherosclerosis was even
more pronounced than in CD40/Apoe/ mice, likely be
cause of the effects of residual CD40-TRAF2/3/5 signaling on

Figure 4. Deficiency in CD40 induces polarization of macrophages
toward a regulatory M2 macrophage phenotype. BM-derived macrophages of WT and CD40/ mice were cultured, stimulated with 1 µg/ml
of the CD40-clustering antibody FGK45, and analyzed for expression of
different M1 (a) and M2 (b, wound-healing macrophages; c, regulatory
macrophages) subset markers by real-time PCR. n = 6 per group of two
independent experiments. Error bars represent mean ± SEM. *, P < 0.05.
JEM VOL. 207, February 15, 2010

regulatory T lymphocytes. Concomitantly, macrophage, CD45+
cell, and CD3+ T lymphocyte infiltration, but also collagen
(I and III), -SMA, and MMP-2 and MMP-9 content, were
substantially reduced in the hardly evolved lesions of CD40T6/ mice (Fig. 5, b and c; Fig. 6; and Fig. S5).
The population of peripheral blood Ly6Chigh monocytes
was significantly declined (Fig. 7 a). Moreover, CD40-T6/
macrophages had an impaired capacity to migrate toward
CCL2 (Fig. 7 b). Intravital microscopy showed that the adhe
sion of circulating leukocytes and, in particular, that of Ly6C+
monocytes to carotid arteries was significantly impaired in
CD40-T6/ mice (Fig. 7, c and d).
CD40-TRAF6 deficiency polarizes macrophages
toward a regulatory M2 phenotype
BM-derived macrophages of CD40-T6/ mice stimulated
with FGK45 produced less IL-12 and iNOS but increased
amounts of IL-10 (Fig. 8), indicating that CD40-TRAF6 defi
ciency skews macrophage polarization toward an antiin
flammatory M2 phenotype. Further subtyping of the M2
macrophages into wound-healing and regulatory macro
phages (Mosser and Edwards, 2008) showed that CD40–TRAF6
interactions did not affect the wound-healing macrophage
markers YM-1, RELM-, arginase I, IGF1, or DCIR but
markedly dampened the M1 polarization response and, rather,
induced a regulatory macrophage subtype that produces high
amounts of IL-10. Importantly, the process of monocyte re
cruitment driven by CD40-TRAF6 was mediated by IL-10, as
treatment of CD40-T6/ mice with a blocking antibody to
IL-10 reversed the protective effect on Ly6C+ cell numbers and
adhesion (Fig. 7 d). The phenotype that occurs in CD40-T6/
mice is likely associated with an impaired NF-B signaling
because IB levels in macrophages were markedly decreased
(Fig. 8 d). Consistent with findings in CD40-deficient macro
phages, CD40-T6/ macrophages displayed a reduced gelati
nolytic activity and increased expression of TIMP-1 (Fig. S5, c
and d). Flow cytometry analysis further revealed reduced num
bers of CD4+CD44highCD62Llow promigratory effector mem
ory T lymphocytes and plasmacytoid DCs (Figs. S3, c and d).
Deficiency of CD40–TRAF2/3/5/6 interactions induces
plaque fibrosis
It is of note that mice with a combined deficiency in CD40TRAF2/3/5/6 binding were characterized by an intermediate
phenotype, further supporting counter-curing effects of CD40TRAF2/3/5 and CD40-TRAF6 signaling in atherosclerosis.
CD40-T2/3/5/6/ mice showed only a slight reduction in
atherosclerosis (Fig. 5 a) but displayed features of atheroscle
rotic plaque stability (Fig. 5 a), with an increased number of fi
brocalcific plaques containing smaller lipid cores and reduced
CD45+ cell and CD3+ T lymphocyte infiltrations.
Plaques of CD40-T2/3/5/6/ mice exhibited high lev
els of collagen (Fig. 6, a–c) and -SMA–positive SMCs (3.1 ±
0.7 vs. 5.1 ± 0.9; P < 0.05). Polarized light microscopy on
Sirius red–stained sections further showed that the majority of
this collagen consisted of large fibrils, as evident by the high
397

Figure 5. Role of CD40-TRAF signaling in atherosclerosis. CD40-Twt (n = 12), CD40-T2/3/5/ (n = 16), CD40-T6/ (n = 19), and CD40T2/3/5/6/ (n = 14) were backcrossed to Apoe/ mice and fed a normal chow diet for 26 wk. (a–d) Sections of the aortic arch and its main branch
points (a; brachiocephalic artery, right subclavian artery, right carotid artery, left carotid artery, and left subclavian artery) were stained with hematoxylin
and eosin (HE) to analyze the extent of atherosclerosis (plaque area) and plaque phenotype. (a) Plaque area and distribution of morphological plaque
phenotypes according to the classification by Virmani et al. (2000; top; horizontal bars represent mean). Representative hematoxylin and eosin–stained
sections in the middle and on the bottom reveal only limited atherosclerosis in absence of CD40-T6 signaling (bars: [middle] 2 mm; [bottom] 100 µm).
(b–d) CD40-T6/ mice have small atherosclerotic lesions that contain few macrophages (b), CD45+ cells, and CD3+ T cells (c). The level of cleaved caspase
3 was determined by grading plaque from 0 (no expression) to 3 (high expression; d). Error bars represent mean ± SEM. *, P < 0.05.
398
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percentage of the red fraction (Fig. 8, c and d). In concor
dance with this finding, plaque levels of collagen I were sig
nificantly increased, whereas collagen III levels were unaffected
(Fig. 6, e and f). Moreover, plaque MMP-2 and MMP-9 lev
els were significantly reduced in CD40-T2/3/5/6/ mice
(Fig. S5, a and b), indicating a decreased proteolytic activity in
these plaques. Accordingly, BM-derived macrophages of
CD40-T2/3/5/6/ mice treated with CD40-clustering anti
body FGK45 displayed reduced gelatinolytic activity and ele
vated levels of TIMP-1 mRNA (Fig. S5, c–e).
As in CD40-T6/ mice, macrophages of CD40T2/3/5/6/ mice stimulated with FGK45 exhibited an M2
macrophage profile with decreased IL-12 production and in

creased production of IL-10, whereas ly6Chigh monocyte num
bers and adhesive function were unaffected (Figs. 7 and 8).
CD40-T2/3/5/6/ mice shared increased CD8+ effector
memory T lymphocytes with CD40-T2/3/5/ mice and
decreased plasmacytoid DC numbers with CD40-T6/ mice
(Fig. S3, c and d). This indicates that some features, namely
reduced inflammatory monocyte arrest and macrophage po
larization, are exclusive to CD40-T6/ mice and are not
compensated for by deficiency of both TRAF binding sites.
DISCUSSION
In this study, we found a clearly divergent action of the two
TRAF binding sites of CD40 in atherosclerosis. Deficiency of

Figure 6. Role of CD40-TRAF signaling in plaque fibrosis. (a–c) Sirius red–stained sections showed low levels of collagen in the initial plaques of
CD40-T6/ mice and increased levels in plaques of CD40-T2/3/5/6/ mice (bars, 50 µm). Collagen content was assessed by light (a) and polarized light
(b) microscopy and expressed as the percentage of Sirius red–stained plaque area (right). In addition, the color spectrum obtained under polarization
microscopy was analyzed (c). (d and e) The content of collagen I (d) and collagen III (e) was assessed by immunohistochemistry (representative sections
on the left; bars, 100 µm) and expressed as the percentage of positively stained plaque area (right). Error bars represent mean ± SEM. *, P < 0.05.
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CD40–TRAF6 interactions in MHCII+ cells nearly abrogated
atherosclerosis, an effect more marked than CD40 deletion it
self, whereas deficiency of CD40–TRAF2/3/5 interactions
did not affect atherosclerosis but, rather, showed a tendency
to aggravate atherosclerosis. The CD40–TRAF6 interactions
appeared to be specifically required for the proatherogenic ac
tivity exerted by cells of the myeloid lineage. Deficiency of
CD40–TRAF6 interactions limits the subset of Ly6Chigh in
flammatory monocytes and attenuates their adhesion to and
infiltration into the arterial wall, thereby abolishing athero
sclerotic plaque formation. The few monocytes that succeed
in infiltrating the arterial wall, rather, differentiate into macro
phages with an antiinflammatory regulatory M2 signature,
thereby preventing plaque inflammation and progression.
In this paper, we provide conclusive evidence for an im
portant role of CD40–TRAF6 interactions in the recruitment
and fate of monocytes/macrophages. Diversity and plasticity
are a hallmark of the monocyte/macrophage lineage, and their
phenotype strongly depends on their microenvironment and
the inflammatory signals they perceive (Gordon, 2003; Mosser
and Edwards, 2008; Auffray et al., 2009). We found that
CD40-TRAF6 signaling affects the homeostasis of both
monocyte and macrophage polarization. CD40-T6/ mice

showed reduced numbers and reduced arterial recruitment of
Ly6Chigh monocytes, the inflammatory monocyte subset
which dominates in hyperlipidemia (Swirski et al., 2007;
Tacke et al., 2007), can easily enter the arterial wall, and can
differentiate into intimal macrophages. In parallel, CD40T6/ mice showed a reduction in the classically activated
M1 macrophage subset producing iNOS and IL-12, which is
involved in clearing intracellular parasites or tumors and elicit
ing tissue disruption (Gordon, 2003; Mosser and Edwards,
2008). Macrophages of CD40-T6/ mice were skewed to
ward the M2 phenotype and particularly toward the IL-10–
producing regulatory subtype (Mosser and Edwards, 2008).
Interestingly, the reduced recruitment of Ly6Chigh mono
cytes in the carotid artery of CD40-T6/ mice could be
reversed by blocking IL-10, indicating that there could be a
link between the IL-10–producing macrophage phenotype
and effects on subsequent monocyte recruitment. Surpris
ingly, markers of the eponymously termed wound-healing
macrophages, which contribute to the healing response after
tissue destruction, were unaltered in the absence of CD40–
TRAF6 interactions, although high levels of plaque fibrosis
were observed in CD40-T2/3/5/6/ mice. However, the rel
evance of these data has to be further substantiated and validated

Figure 7. CD40-TRAF signaling affects monocyte homeostasis and recruitment. (a) The percentage of Ly6Chigh monocytes is reduced in the peripheral blood of CD40-T6/ mice. Horizontal bars represent the mean. (b) Macrophages deficient in CD40-TRAF6 signaling have an impaired capacity to
migrate toward CCL2 in a Transwell migration assay. (c and d) Accordingly, rhodamine-labeled leukocytes (c) and Ly6C+ monocytes (d) display an impaired
luminal adhesion to the wall of carotid arteries in absence of CD40–T6 interactions in vivo, which is reversed by pretreatment with a blocking antibody to
IL-10 (d). Error bars represent mean ± SEM. *, P < 0.05.
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Figure 8. Deficiency in CD40-TRAF6 interactions induces polarization of macrophages toward a regulatory M2 macrophage phenotype.
(a–c) BM-derived macrophages of CD40-Twt, CD40-T2/3/5/, CD40-T6/, and CD40-T2/3/5/6/ mice were cultured, stimulated with 1 µg/ml of the
CD40-clustering antibody FGK45, and analyzed for expression of different M1 (a) and M2 (b, wound-healing macrophages; c, regulatory macrophages)
subset markers by real-time PCR. n = 6 per group of two independent experiments. (d) The levels of IB in FGK45-stimulated macrophages were
decreased in BM-derived macrophages of CD40-T6/ and CD40-T2/3/5/6/ mice (n = 6). Error bars represent mean ± SEM. *, P < 0.05.
JEM VOL. 207, February 15, 2010

401

because the functional role of different monocyte and macro
phage subsets in atherosclerosis remains to be fully elucidated
(Mantovani et al., 2009; Swirski et al., 2009). For now, our
data clearly reveal that a deficiency of CD40–TRAF6 inter
actions confers an immune-regulatory phenotype in the
monocyte/macrophage lineage, which reduces atherosclerosis
and is capable of inducing plaque stability.
In vascular pathobiology, only few data are available on
the role CD40–TRAF6 interactions. Recently, CD40–
TRAF6 interactions in MHCII+ cells have also been impli
cated in neointima formation in a mouse ligation model
(Donners et al., 2008). Moreover, it has been observed that
stimulation with CD40L induces CD40–TRAF6 interac
tions in endothelial cells but that their disruption surpris
ingly results in increased expression of CCL2 (Zirlik et al.,
2007a). More evidence has been gathered regarding the role
of CD40–TRAF6 interactions in hematopoietic cell types
including cells of the myeloid lineage. In B cells, effects of
CD40-TRAF6 signaling comprise germinal center forma
tion, NF-B activation, IL-6 production, and up-regulation
of costimulatory molecules (Tsukamoto et al., 1999; Ahonen
et al., 2002; Hostager, 2007). In monocytes/macrophages,
CD40–TRAF6 interactions induce NF-B and ERK
activation, as well as the production of TNF- and IL-6
(Mukundan et al., 2005). In DCs, CD40-TRAF6 signaling
is required for MHCII surface expression and IL-6 and IL12 production (Kobayashi et al., 2003). Differences in the
effector functions of CD40-TRAF6 signaling between the
various cell types may be a result of context-specific embed
ding of downstream pathways.
Our data further show that CD40–TRAF2/3/5 interac
tions on MHCII+ cells appear to be required for maintaining
T lymphocyte homeostasis in atherosclerosis. Absence of
CD40–TRAF2/3/5 interactions increased the numbers of
CD4+ T cells and promigratory CD8+CD44highCD62Llow ef
fector memory T lymphocytes, which by itself would likely
be sufficient to aggravate atherosclerosis. However, the
increase in T cells was compensated by an increase in
CD4+CD25+FoxP3+ regulatory T lymphocytes, both sys
temically and in the vasculature. This expansion of regulatory
T cells as an atheroprotective T cell subtype (Ait-Oufella
et al., 2006) may protect CD40-T2/3/5/ mice against the
T cell–induced exacerbation of atherosclerosis.
Data on the role of CD40-T2/3/5 signaling in vascular
biology are scarce and not uniform, as the induction of
CD40-TRAF2/3/5 signaling yields different outcomes de
pending on the cell types and pathologies involved. Consis
tent with the present study, we did not find an effect on
neointima formation after carotid artery ligation in CD40T2/3/5/ mice (Donners et al., 2008). However, TRAF2/
and TRAF5/ endothelial cells failed to produce IL-6
upon stimulation with CD40L, whereas CCL2 induction
was unaffected (Zirlik et al., 2007a). In areas with high shear
stress, TRAF3 expression in endothelial cells covering
human atherosclerotic plaques is up-regulated and may act as
a feedback mechanism limiting endothelial activation, as its
402

overexpression prevented CD40-induced proinflammatory
cytokine expression (Urbich et al., 2001).
A clearer picture of the function of CD40–TRAF2/3/5
interactions has emerged in B cell biology. CD40-TRAF2
signaling is crucial for germinal center formation, induces
JNK activation, and, in particular, NF-B2 activation
(Tsukamoto et al., 1999; Au and Yeh, 2007; Vallabhapurapu
et al., 2008). This is in accordance with our findings that
IB mRNA expression was not significantly decreased in
CD40-T2/3/5/ macrophages. Together with CD40–
TRAF5 interactions, which are also required for Ig produc
tion, CD40-TRAF2 signaling up-regulates costimulatory
molecules (Au and Yeh, 2007). In contrast, TRAF3 acts as an
inhibitor reducing costimulatory molecule expression and
IgM production (Bishop and Xie, 2007). In cell types and
organs other than B cells or lymph nodes, however, most of
these functions are irrelevant. Consistent with our data, the
overall effect of CD40-TRAF2/3/5 signaling with regards to
atherogenesis appears to be balanced.
Our findings may harbor new and interesting therapeutic
possibilities. The complete inhibition of CD40–CD40L sig
naling in atherosclerosis is not therapeutically feasible because
long-term treatment will compromise systemic immune re
sponses and also entails thromboembolic complications.
Therefore, inhibition of the TRAF6 binding site on CD40,
using small molecules or an antagonizing CD40 antibody that
changes the conformation of the CD40-TRAF binding sites,
may be a suitable alternative. It is conceivable that the protec
tion by CD40-TRAF6 blockade is conferred by skewing the
immune response to a more antiinflammatory profile, namely
through increased production of IL-10 and its effects on miti
gating the relative propensity, recruitment, and differentiation
of proinflammatory monocytes. Not only could inhibition of
the CD40-TRAF6 binding site reduce atherosclerosis more
effectively than a complete inhibition of CD40 or CD40L by
avoiding an interference with potentially protective effects by
remaining CD40-signaling pathways, it may also leave the
normal functions of these pathways unaffected, and would
therefore be expected to only cause limited side effects. How
ever, although our results in the mouse model are promising,
caution should be applied when extrapolating these experi
mental data to the human situation. The effects of such selec
tive targeting strategies will have to be meticulously scrutinized
before being translated into a clinical setting.
MATERIALS AND METHODS
Animals. CD40/, CD40-Twt, CD40-T2/3/5/, CD40-T6/, and
CD40-T2/3/5/6/ mice (all on a C57Bl6 background; Ahonen et al.,
2002) were backcrossed for seven generations to Apoe/ mice. Ldlr/ mice
were purchased from The Jackson Laboratory. All study protocols involving
animal experiments were approved by the Animal Care and Use committee
of the University of Maastricht and were performed according to official
rules formulated in the Dutch law on care and use of experimental animals,
which are highly similar to those of the National Institutes of Health.
Primary atherosclerosis. CD40/Apoe/ (n = 16), CD40+/+Apoe/
(n = 19), CD40-Twt (n = 14), CD40-T2/3/5/ (n = 17), CD40-T6/ (n = 26),
and CD40-T2/3/5/6/ (n = 14) mice were fed a normal chow diet through
out the experiment.
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BM transplantation. Ldlr/ mice (n = 44) were maintained in filter-top
cages and given water containing 60,000 U/liter polymyxin B sulfate (Invit
rogen) and 100 mg/liter neomycin (Invitrogen) from 1 wk before BM trans
plantation until 4 wk thereafter. Mice were lethally irradiated (10 Gy,
0.5 Gy/min; MU 15F/225 kV; Philips) and i.v. injected with 107 BM cells
from CD40/ mice or CD40+/+ mice. 4 wk after transplantation, mice
were fed a 1.25% cholesterol diet for 24 wk.
Atherosclerosis experiments. Mice were sacrificed and the arterial tree was
perfused. The aortic arch and its main branch points were excised, fixed over
night, and embedded in paraffin. The rest of the arterial tree was fixed, opened,
pinned, and stained with Oil-red-O for en face analysis. Longitudinal sections
of the aortic arch were analyzed for plaque extent and phenotype as previously
described (Virmani et al., 2000; Lutgens et al., 2006). For phenotypic parame
ters, immunohistochemistry was performed for CD3 (Dako), CD45 (BD),
mac-3 (BD), FVIII (Dako), -SMA (Sigma-Aldrich), caspase 3 (Cell Signaling
Technology), FoxP3 (eBioscience), collagen I (Abcam), collagen III (Abcam),
MMP-2 (Cell Signaling Technology), MMP-9 (Santa Cruz Biotechnology,
Inc.). In addition, Perl’s iron staining and Sirius red staining were as previously
described (Lutgens et al., 2006). Morphometric analyses were performed using
a Quantimet (Leica) with Qwin3 software (Leica). Plasma cholesterol levels
were measured enzymatically (Roche), organs were analyzed by hematoxylin
and eosin staining, and no abnormalities were observed. Serum sCD40L levels
were measured by ELISA (eBioscience).
In vitro macrophage culture. BM cells were isolated from n = 6 mice/
group and cultured in RPMI supplemented with L929 conditioned medium
to generate BM-derived macrophages as previously described (Kanters et al.,
2003). Cells were pretreated with 100 U IFN-g for 24 h to induce MHCII
expression and then treated for 3 h with 100 ng/ml FGK45, a CD40-stimulat
ing antibody. Cytokine levels in the medium were measured by FACS using
a cytometric bead assay (BD), and quantitative gene expression of cytokines,
M1, and M2 macrophage markers were analyzed as previously described
(Beckers et al., 2007).
Macrophage migration assay. Macrophage migration was assessed using
24-well Transwell migration chambers (Costar; Corning) with a pore size of
6 µm. BM-derived macrophages (0.5 × 106) of the respective genotypes, sus
pended in serum-free medium, were added to each chamber. Complete me
dium, including 100 ng/ml CCL2 (R&D Systems), was added to the lower
chambers and migration was performed at 37°C for 4 h. Nonmigrated cells
were removed from the membranes, and migrated cells within the membrane
were fixed with methanol and stained with toluidine blue. Membranes were
cut out of inserts and mounted onto slides in immersion oil. The number of
migrated cells was counted on five randomly chosen fields of each membrane.
Gelatinase assay. Gelatinase activity in the supernatant of FGK45-treated
macrophages was determined using the EnzChek gelatinase/collagenase assay
kit (Invitrogen). Substrate hydrolysis was analyzed after 24 h at room tempera
ture and fluorescence was detected using a fluorescence microplate reader.
Intravital microscopy. Leukocyte endothelial interactions were analyzed
by intravital microscopy of the left carotid artery (n = 8 mice/group; Koenen
et al., 2009). 6 h after i.p. injection of 1.0 µg of mouse TNF (PeproTech),
mice were anaesthetized with ketamine/xylazine and the left carotid artery
was exposed. Circulating leukocytes were labeled by i.v. injection of rhoda
mine 6G. Ly6C+ inflammatory monocytes were labeled with fluorescent
latex beads as previously described (Soehnlein et al., 2008). The antibody to
IL-10 (clone JES5.2A) was injected twice i.p. (500 µg/mouse), 24 and 2 h
before intravital microscopy. Recordings were made using a microscope
(BX51; Olympus) equipped with a saline-immersion 20× objective.
Statistics. Data are presented as mean ± SEM. Data were analyzed by a
nonparametric Mann-Whitney U test or Welch-corrected t test, as appropri
ate, using Prism 4 software (GraphPad Software, Inc.). P-values <0.05 were
considered significant.
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Online supplemental material. Fig. S1 shows additional phenotypic fea
tures of the atherosclerotic plaques of CD40/Apoe/ mice (classification
of Virmani et al. [2000], Caspase 3 and FoxP3 levels). Fig. S2 shows MMP-2
and MMP-9 levels in plaques of CD40/Apoe/ mice, as well as gelatinase
activity and TIMP-1 levels in their BM-derived macrophages. Fig. S3 shows
the extended immune phenotyping of splenocytes in all the experimental
groups. Fig. S4 shows the balanced effector T cell phenotype in absence of
CD40-TRAF2/3/5 interactions. Fig. S5 shows MMP-2 and MMP-9 levels
in plaques of the CD40-TRAF mice, as well as gelatinase activity and TIMP-1
levels in their BM-derived macrophages. Online supplemental material is
available at http://www.jem.org/cgi/content/full/jem.20091293/DC1.
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